The Treatment Of Drug Store Advantage Administrators

The utilization of prescription drugs has increased across all age groups in the US, with 50% of Americans taking at least one prescription drug (Rice & Unruh, 2016). This can be attributed to physician-induced demand, substitution of pharmaceuticals for other medical regimens, commercialization of the products, increase in the aging population and drug insurance coverage, and also the increase in chronic conditions. Lathan discusses the startling fact that the rate increase of prescription drugs purchased was considerably higher in contrast to the US population growth - 71% and 9% respectively (Rice & Unruh, 2016, p. 264).

Imagine this: you are tragically diagnosed with a chronic life-threatening illness. Your only hope to survive is through medication to treat your disorder. The medicine is pricy but you can work out the costs each month. One day, you go to fill your prescriptions and realize the cost of a $13 pill has jumped to an astounding $750. You need this patented medication to survive and to afford it you end up losing your home, filing for bankruptcy, and sleeping in your car. This story sounds fictional but it is the reality for many Americans who can no longer afford their grossly overpriced medications.

"In the past two decades or so, health care has been commercialized as never before, and professionalism in medicine seems to be giving way to entrepreneurialism," commented Arnold S. Relman, professor of medicine and social medicine at Harvard Medical School (Wekesser 66). This statement may have a great deal of bearing on reality. The tangled knot of insurers, physicians, drug companies, and hospitals that we call our health system are not as unselfish and focused on the patients' needs as people would like to think. Pharmaceutical companies are particularly ruthless, many of them spending millions of dollars per year to convince doctors to prescribe their drugs and to convince consumers that their specific brand of drug is needed in

are going about trying to dispense their own medications. Texas physicians have started fighting for dispensing privileges

Some of the current changes that can be seen in regards to prescription privileges include changes in the ways that physicians and mental health professionals are able to prescribe medications to their patients. According to Brenda Smith of the APA (2012), currently patients receive their medications for psychological conditions by a physician usually without having been evaluated by a mental health practitioner according to the CDC. The trend includes individuals to visit their general health practitioners in order to receive psychotropic medications such as antidepressants and anxiolytics. The problem with individuals receiving these medications from other sources include: deterrence

Many experts in healthcare economics point out that chronic medical conditions are directly associated with higher costs (G., 2010). This association is mainly attributed to the high usage of all types of care (Kongstvedt, 2013). Reports show that the number of people suffering with chronic conditions is radically rising and forecasts suggest that the number of American’s with one or more chronic conditions will continue to grow by an estimated 37% between 2000 and 2030 (G., 2010). It is in our patient’s main interest to shift our current focus from treatment for acute conditions to target a better utilization of the recorded 78% of health spending devoted to people with chronic conditions. The new strategic approach is one of developing quality medical care for people with chronic conditions which require ongoing care and care management to improve their health status (Kongstvedt, 2013).

We in America tend to take medications for almost any problem we have, from headaches to gastrointestinal pain, to more serious chronic disorders such as depression and attention deficit disorder. While many of the uses of such medications may be necessary and legitimate, many are not, and due to this fact, many people become dependent on medications, mentally, and or physically. This problem is not simply the fault of the individual; in fact, the blame can also be placed upon the medical community, and the pharmaceutical companies who produce the drugs. How often can one turn on the television to see advertisements for Claritin, Aspirin, Pepto-Bismol, or even Zoloft or Ritalin? The pharmaceutical industry is motivated by monetary

- The following legislations have a direct impact on the handling of medications within a social care setting:

The HRSA allowed those eligible entities, even those with in-house pharmacies to contract with outside pharmacies, “In one year, from April 2010- April 2011, the number of contract pharmacy arrangements grew by 161 percent. Based on historical contract adoption rates, by 2019, 90% of DSH hospitals will have contracts with pharmacies as part of their 340B operations. Since, DSH hospitals account for 81 percent of total 340B sales; they will be the primary driver of 340B utilization growth through contract pharmacies,” (Vandervelde, 2014, & Avalere Health, 2011). Pharmacy expansion contracts were supposed to help small clinics without their own in-house pharmacy, but, it seems all 340Be entities are benefiting even the large non-profit hospitals. Hence, those clinics that are treating the uninsured and indigent are not truly the entities benefitting from the

Conclusion: Ultimately, a pharmacist’s role would greatly expand with the Provider Status law. In the future, all states should adapt a form of the Provider Status law. Pharmacists should be utilized to their utmost capabilities, they endured four years of education studying medications, their uses and the effects. A pharmacist’s expertise is very vital to a patient’s treatment. Eventually, pharmacists should be granted the right to prescribe

People all over the world, continue to be tendered prescription medication, which in many cases further complicate health issues with its myriad of side effects. In fact, statistics have shown that approximately 100,000 people around the world die as a result of prescription drugs annually (Smith, 2012). On the contrary, according

The rise in costs of prescription medicines affects all sectors of the health care industry, including private insurers, public programs, and patients. Spending on prescription drugs continues to be an important health care concern, particularly in light of rising pharmaceutical costs, the aging population, and increased use of costly specialty drugs. In recent history, increases in prescription drug costs have outpaced other categories of health care spending, rising rapidly throughout the latter half of the 1990s and early 2000s. (Kaiseredu.org, 2012).

Prescription medications serve the purpose of helping individuals with symptoms that are occurring in the short term. The perception people have on prescribed medication is widely positive due to the high number of daily consumers, but the world is only viewing the positives on this controversial topic. Consumers who have illnesses should not rely on prescription medications due to the negative side effects, high addiction rates and potential increase in crime proving that home remedies are much more reliable, healthier and safer alternatives.

Create policy around how we develop formulary and add meds. This policy is planned to be developed in 2016.

Recently, there has been a debate about the high prescription drug prices in the United States. Accounting for 9.7% of the national health expenditure, $329.2 billion was spent on prescription medications ($931 per person) in 2011 (Linton, 2014). So what exactly is the average American getting with their $931? Well, because there is an extraordinary amount of time, effort, and energy that goes into creating, manufacturing, and distributing a new drug, it’s no wonder the prices are so high. But what other costs are folded into the prices of your prescribed medications? This review looks beyond just the research and development costs needed to take a new drug from idea to shelf by examining several journals and other credible, secondary sources, to shed some light on how much pharmaceutical companies are spending to develop, advertise, and sell their drugs.